On January 24, 2023 PharmaMar (MSE:PHM) has reported that its licensing partner, Adium Pharma, has received the full approval for commercialization for Zepzelca (lurbinectedin) by the Federal Commission for the Protection against Sanitary Risks of Mexico (COFEPRIS) for the treatment of adult patients with metastatic Small Cell Lung Cancer (SCLC) with disease progression on or after platinum-based chemotherapy (Press release, PharmaMar, JAN 24, 2023, View Source [SID1234626497]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

This new approval of lurbinectedin is based on the monotherapy clinical data from the open-label, multi-center, single-arm clinical trial in 105 adult patients with relapsed SCLC (including patients with platinum-sensitive and platinum-resistant disease), that the Food and Drug Administration (FDA) used to grant accelerated approval for lurbinectedin in the US.

In March 2021, PharmaMar and Adium Pharma signed a licensing agreement for lurbinectedin in Latin America. The Mexican approval of lurbinectedin has been preceded for Adium by the approval in November 2022 also in Ecuador.

These approvals allow Adium Pharma to commercialize lurbinectedin in Ecuador and Mexico in the following months. SCLC accounted for up to 15% of all lung cancer cases[1]. Most SCLC patients are already at the advanced stage upon diagnosis, resulting in poor prognosis.